The Innovation Engine Driving a Revolution in Infection Control

Breakthrough patented technology.

Shielding against the nastiest pathogens.

Revolutionizing medical science.

Asepticys is turning this pioneering technology into a pipeline of new anti-infective products and applications to protect your health.

See More of the Asepticys Story
Multiple modes of action in a single product
Kills bacteria, viruses, fungi and protozoa
Rapidly disinfects and sterilizes
Safe for use on human skin, eyes and tissue
Patent protected

Company Highlights

Novel Anti-Infective Compound
Discovered at Tulane University
IP through 2036 and beyond; Exclusively licensed to Asepticys
New chemical entity; not used for any prior Rx/OTC product
Established Safety
First human clinical trial completed in 2018
Data confirms safe for disinfection of contact lenses for use in eye
Next anti-viral product advancing through pre-clinical studies for INDA filing in late 2019 / early 2020
TriFlect™ Technology
Fast-acting biocidal activity against bacterial, fungal, and viral pathogens creates opportunities for multiple Rx and OTC products
Commercial launch of lead product in 2019
All pipeline products significantly out-perform existing commercial products

IP Protection

Asepticys has secured broad global rights to TriFlect™ technology.
Exclusive global license to broad IP from Tulane University
Global Asepticys IP Estate continues expanding with new R&D discoveries
New chemical entity – not previously used for any pharmaceutical
IP coverage for 2036 and beyond
Key markets protected include the United States, Japan, China, Korea, Australia, Europe, Switzerland, Brazil, Mexico, Canada